Table 1 Summary of the results of demographics, disease and drug details of patients with and without neutropenia receiving anti‐tumour necrosis factor treatment.
| Neutropenia (<2.0×109/l) (%) | No neutropenia (%) | Statistics | |
|---|---|---|---|
| n (%) | 19 (14.3) | 114 (85.7) | |
| Female | 16 (15.4) | 88 (84.6) | χ2 = 0.47, p = 0.5 |
| Male | 3 (10.3) | 26 (89.7) | |
| Mean age (years) | 57.4 | 56.6 | t = 0.25, p = 0.8 |
| Anti‐TNF drugs | |||
| Adalimumab | 3 (14.3) | 18 (85.7) | χ2 = 0.08 |
| Etanercept | 13(15.3) | 62 (84.7) | p = 0.96 |
| Infliximab | 3 (13.1) | 20 (86.9) | |
| Baseline neutrophil count | 3.77 | 6.12 | t = 4.85, p<0.001 |
| Baseline total white cell count | 5.88 | 8.82 | t = 5.23, p<0.001 |
| Neutrophils:white cell count ratio | 0.62 | 0.68 | t = 2.73, p = 0.007 |
| ANA positive | 7/65 (10.8) | 58/65 (89.2) | χ2 = 0.001, p = 0.97 |
| ANA negative | 4/38 (10.5) | 34/38 (89.5) | |
| On methotrexate | 5/47 (10.6) | 42/47 (89.4) | χ2 = 0.79, p = 0.37 |
| Not on methotrexate | 14/86 (16.3) | 72/86 (83.7) | |
| On prednisolone | 4/53 (7.5) | 49/53 (92.5) | χ2 = 3.2, p = 0.07 |
| Not on prednisolone | 15/80 (18.8) | 65/80 (81.2) | |
| Neutropenia on previous DMARDs | |||
| Yes | 11/23(47.8) | 12/23 (53.2) | χ2 = 25.5, p<0.001 |
| No | 8/110 (7.3) | 102/110 (82.7) |
ANA, antinuclear antibodies; DMARDs, disease‐modifying antirheumatic drugs; TNF, tumour necrosis factor.